Granted Patent
B2
US 11,077,094 · App. 16/536,582 · Granted Aug 3, 2021
Spiro-lactam NMDA receptor modulators and uses thereof
Assignee:
Aptinyx Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
Claims (6)
1. A compound represented by:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition, the pharmaceutical composition comprising:
a compound represented by:
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 1, 2023
From: APTINYX INC.
To: TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED
Reel/Frame 065426/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 4, 2020
From: LOWE, JOHN A., III; KHAN, M. AMIN
To: NAUREX, INC.
Reel/Frame 051416/0919 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 4, 2020
From: NAUREX, INC.
To: APTINYX INC.
Reel/Frame 051416/0929 →
Continuity (5)
Continuation
14764395
Provisional Application
61757903
· Jan 29, 2013